Literature DB >> 27525808

The Burden of Comorbidity Is Associated with Antibiotic Resistance Among Institutionalized Elderly with Urinary Infection: A Retrospective Cohort Study in a Single Italian Nursing Home Between 2009 and 2014.

Alice Laudisio1, Felice Marinosci2, Antonella Gemma3, Isaura Rossi Bartoli1, Nicola Montenegro1,2, Raffaele Antonelli Incalzi1,2.   

Abstract

Urinary tract infections (UTIs), which are common among nursing home patients, are associated with adverse outcomes and increased healthcare costs. Antibiotic resistance is an emerging problem, associated with excess morbidity and mortality; it has been suggested that this condition might be more prevalent among subjects with comorbid conditions. The aim of this study was to assess the association, if any, of antibiotic resistance with the burden of comorbidity in elderly with UTIs. This retrospective study enrolled 299 patients with culture-positive UTI consecutively admitted to the nursing home of the "Fondazione San Raffaele Cittadella della Carità", Taranto, Italy, which includes 80 beds under the direction of two geriatricians. The burden of comorbidity was quantified using the Charlson comorbidity score index. Diagnosis of UTI was ascertained by urine culture. Antibiotic resistance was defined according to the European Centre for Disease Prevention and Control expert proposal. Logistic regression was used to assess the adjusted association of the variables of interest with the presence of antibiotic resistance. Antibiotic resistance was detected in 162/299 (54%) patients. In logistic regression, the presence of antibiotic resistance was independently associated with higher Charlson score, after adjusting (odds ratio = 1.06; 95% confidence interval = 1.01-1.10). Antibiotic resistance is highly prevalent among nursing home residents; it is associated with the burden of comorbidity, but not with single diseases. This association and its potential implications should be assessed in dedicated studies.

Entities:  

Keywords:  antibiotic resistance; comorbidity; epidemiology; nursing home; urinary infection

Mesh:

Substances:

Year:  2016        PMID: 27525808     DOI: 10.1089/mdr.2016.0016

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  5 in total

1.  The rise in vancomycin-resistant Enterococcus faecium in Germany: data from the German Antimicrobial Resistance Surveillance (ARS).

Authors:  Robby Markwart; Niklas Willrich; Sebastian Haller; Ines Noll; Uwe Koppe; Guido Werner; Tim Eckmanns; Annicka Reuss
Journal:  Antimicrob Resist Infect Control       Date:  2019-08-28       Impact factor: 4.887

2.  The ongoing challenge of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis in Europe: an epidemiological analysis of bloodstream infections.

Authors:  Olaniyi Ayobami; Niklas Willrich; Annicka Reuss; Tim Eckmanns; Robby Markwart
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

3.  The epidemiology of carbapenem resistance in Acinetobacter baumannii complex in Germany (2014-2018): an analysis of data from the national Antimicrobial Resistance Surveillance system.

Authors:  Dunja Said; Niklas Willrich; Olaniyi Ayobami; Ines Noll; Tim Eckmanns; Robby Markwart
Journal:  Antimicrob Resist Infect Control       Date:  2021-03-01       Impact factor: 4.887

4.  Trends and impact of antimicrobial resistance on older inpatients with urinary tract infections (UTIs): A national retrospective observational study.

Authors:  Hoa Q Nguyen; Nga T Q Nguyen; Carmel M Hughes; Ciaran O'Neill
Journal:  PLoS One       Date:  2019-10-03       Impact factor: 3.240

5.  Human MAIT cell cytolytic effector proteins synergize to overcome carbapenem resistance in Escherichia coli.

Authors:  Caroline Boulouis; Wan Rong Sia; Muhammad Yaaseen Gulam; Jocelyn Qi Min Teo; Yi Tian Png; Thanh Kha Phan; Jeffrey Y W Mak; David P Fairlie; Ivan K H Poon; Tse Hsien Koh; Peter Bergman; Chwee Ming Lim; Lin-Fa Wang; Andrea Lay Hoon Kwa; Johan K Sandberg; Edwin Leeansyah
Journal:  PLoS Biol       Date:  2020-06-08       Impact factor: 8.029

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.